) greatly decreased or abolished G protein and PLC-␤ activities and inhibition of adenylyl cyclase. This implies that sequences NH2-terminal to the motif or COOH-terminal to R 470 could not sustain receptor activity in situ, although they exhibited activity when used as synthetic peptides. Deletion of the 11 COOH-terminal residues (E 486 to A
496
) suggested an autoinhibitory function for this sequence. We conclude that the 17-amino acid sequence (R 469 to R 485 ) in the middle region of the intracellular domain of NPR-C is both necessary and sufficient for activation of G proteins and effector enzymes. phospholipase C-␤; adenylyl cyclase; G protein-coupled receptors; natriuretic peptide clearance receptor G PROTEIN-ACTIVATING SEQUENCES have been identified in the intracellular domains of various single-transmembrane receptors. Okamoto et al. (13) have shown that a 14-amino acid intracellular sequence of the human insulin-like (IGF) II/mannose 6-phosphate receptor activates pertussis toxin-sensitive G proteins (G i2 Ͼ G i1 Ն G i3 Ͼ G o ). The sequence is characterized by the presence of two NH 2 -terminal basic residues and a COOH-terminal motif BBXXB, where B and X represent basic and nonbasic residues, respectively (13) (14) (15) (16) 22) . Synthetic short cationic peptides containing 10-26 amino acid residues with a pair of NH 2 -terminal basic residues and COOH-terminal BBXXB, BBXB, or BXB motifs activate G proteins, usually one or more isoforms of G i (4, 9, 23) . Similar active sequences have been identified in the cytoplasmic regions of seventransmembrane muscarinic m1-m5 and adrenergic ␣ 2 and ␣ 1b receptors and in the COOH-terminal region of the 7-to 11-transmembrane polycystin-1 receptor (14, 19, 22, 26) .
The single-transmembrane natriuretic peptide clearance receptor, NPR-C, has been shown to inhibit adenylyl cyclase in a G protein-dependent, pertussis toxin-sensitive fashion (1, 11, 18) . A synthetic peptide corresponding to the entire 37-amino acid intracellular domain of NPR-C inhibited adenylyl cyclase in rat cardiac membranes, and a polyclonal antibody to this peptide blocked atrial natriuretic peptide (ANP)-induced inhibition of adenylyl cyclase (2) . Our studies in smooth muscle cells have identified G i1 and G i2 as the G proteins selectively activated by NPR-C (9-11). NPR-C is widely expressed in vascular and visceral smooth muscle. In smooth muscle of the gut, NPR-C is coexpressed with NPR-B but not NPR-A (10, 11) . In gastric and intestinal smooth muscle cells that also express nitric oxide synthase III (NOS-III), NPR-C activated NOS-III and inhibited adenylyl cyclase via the ␣-subunits of both G i1 and G i2 (10) . In NOS-deficient cells, such as smooth muscle cells from guinea pig tenia coli, NPR-C inhibited adenylyl cyclase via the ␣-subunits of G i1 and G i2 and activated phospholipase C (PLC)-␤3 via the ␤␥-subunits (11). The G proteinactivating domain of NPR-C was determined by using receptor-derived synthetic peptides corresponding to NH 2 -terminal, COOH-terminal, and middle regions of the 37-amino acid intracellular domain of human NPR-C (9 485 (BBXXB), selectively activated G i1 and G i2 , inhibited adenylyl cyclase via the ␣-subunits, and activated PLC-␤3 via the ␤␥-subunits in permeabilized tenia smooth muscle cells and in smooth muscle membranes in a similar fashion to the selective NPR-C ligand, cANP4-23 (9) . Cotransfection of NPR-C and NOS-III into COS-1 cells or transfection of NOS-III into cultured tenia coli muscle cells confirmed the ability of NPR-C to activate NOS-III (10).
The intracellular domain of rat NPR-C is similar but not identical to that of human NPR-C and contains several sequences that could potentially activate G proteins. Several peptides corresponding to these sequences were shown to inhibit adenylyl cyclase in cardiac and vascular smooth muscle membranes, including a 17-amino acid sequence from the middle region that was similar to the active sequence derived from human NPR-C (9, 17) . The study raised the possibility that more than one region of the intracellular domain of rat NPR-C could participate in G protein activation. Although synthetic peptides are useful in locating G protein-activating sequences in the intracellular domain, they do not provide decisive evidence as to which sequence of the receptor in situ activates specific G proteins.
In the present study, we attempted to resolve this issue by deletion and site-directed mutagenesis of critical basic residues. Nine mutant NPR-C receptors were constructed in which single or dual basic amino residues in the NH 2 -terminal (BB) or COOH-terminal motif (BBXXB) were mutated to Leu. The mutants were stably expressed in COS-1 cells, and the activities of G i1/2 , PLC-␤, and adenylyl cyclase were determined in response to cANP4-23. The results indicate that the 17-amino acid sequence in the middle region of the intracellular domain of rat NPR-C is the only G protein-activating sequence of the receptor in situ.
MATERIALS AND METHODS

Construction of mutant receptor cDNAs.
Mutant receptor cDNAs were constructed by the Megaprimer method (20) , with three PCR primers used to perform two rounds of PCR. The product of the first PCR was used as one of the PCR primers for the second PCR. PCR was performed under standard conditions [10 mM KCl, 10 mM (NH 4)2 SO4, 20 mM Tris ⅐ HCl, 2 mM MgSO4, pH 8.8, 200 M dNTP, and 100 ng of each primer] in a final volume of 50 l using 2.5 units of pfu DNA polymerase. The wild-type rat NPRC receptor cDNA subcloned into pcDNA3 was used as the template. COOHterminal deletion mutant cDNAs were amplified by PCR using Taq DNA polymerase, and all the mutant cDNAs were subcloned into pcDNA3 expression vector. Mutants were sequenced to confirm that the mutagenesis or deletion was successful. The primer sequences are listed in Table 1 .
The sequence of the G protein-activating peptide derived from the middle region of the intracellular domain was used as a guide in the construction of mutants. The sequences of the intracellular domain of rat wild-type and nine mutant NPR-C receptors are listed in Fig. 1 with 10% fetal bovine serum, penicillin (50 U/ml), streptomycin (50 g/ml), and gentamicin (100 g/ml) at 37°C in a humidified atmosphere of 95% air and 5% CO 2. The pcDNA3 expression vector containing either wildtype or mutant cDNA NPR-C was transfected into COS-1 cells using Lipofectamine. Transfected cells were isolated in a medium containing 500 g/ml geneticin (G418). G418-resistant cells were recultured, and confluent monolayers were screened for expression of wild-type and mutant NPR-C by RT-PCR and radioligand binding using [
125 I]ANP. Selection pressure for clonal cell lines was maintained by the addition of 100 g/ml G418 to the culture medium. For all studies, transfected cells in monolayers at ϳ90% confluence were utilized.
[ 125 I]ANP binding assay. Confluent cultures of COS-1 cells were detached with 0.25% trypsin and 1 mM EDTA. Cells were immediately centrifuged at 500 g for 5 min at 4°C. The cell pellet was washed with phosphate-buffered saline (PBS) and homogenized. The homogenate was centrifuged at 30,000 g for 30 min at 4°C, and the membrane pellet was suspended in 50 mM Tris ⅐ HCl containing 5 mM MgCl 2, 0.5% BSA, 0.5% bacitracin, and 10 g/ml aprotinin. Membranes (30 g) were incubated with 50 pM 125 I-labeled ANP at 25°C for 30 min in the presence or absence of various concentrations of unlabeled cANP-4-23. The reaction was terminated with the addition of 5 ml of ice-cold PBS. The solution was filtered under vacuum through a Whatman GF/C glass filter, and the filter was then washed three times with 5 ml of PBS. The radioactivity retained on the filter was counted, and the specific binding was calculated as the difference between Table 1 . Sequence of PCR primers used to construct NPR-C mutants total binding and nonspecific binding measured in the presence of 10 M cANP4-23.
Assay of PLC-␤ activity. Inositol phosphates were measured as described previously using anion exchange chromatography (9) (10) (11) 25) . COS-1 cells expressing wild-type or mutant rat NPR-C in six-well culture plates were labeled with myo- [2] [3] H]inositol in inositol-free DMEM (1 Ci/well) for 24 h. The cells were washed with PBS and treated with cANP4-23 for 60 s in 1 ml of 25 mM HEPES medium (pH 7.4) consisting (in mM) of 115 NaCl, 5.8 KCl, 2.1 KH 2P04, 2 CaCl 2, 0.6 MgCl2, and 14 glucose. The buffer was aspirated, and the reaction was terminated by the addition of 940 l of chloroform-methanol-HCl (50:100:1). The samples were extracted with 340 l of chloroform and 340 l of H 2O and centrifuged at 1,000 g for 15 min. The upper aqueous phase was applied to DOWEX AG-1 column. The column was washed with 10 ml of H 2O and 10 ml of 5 mM sodium tetraborate-60 mM ammonium formate. The [ (12) as described previously (9) (10) (11) . COS-1 cells were homogenized in 20 mM HEPES (pH 7.4) containing 2 mM MgCl 2, 1 mM EDTA, and 2 mM 1,4-dithiothreitol (DTT). The homogenate was centrifuged at 30,000 g for 30 min at 4°C, and the membranes were solubilized at 4°C in 20 mM HEPES (pH 7.4) buffer containing 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The cell membranes were incubated with 100 nM [
35 S]GTP␥S in a solution containing 10 mM HEPES (pH 7.4), 0.1 mM EDTA, and 10 mM MgCl 2 for 20 min at 37°C in the presence or absence of agonist. The reaction was stopped with 10 volumes of 100 mM Tris ⅐ HCl (pH 8.0) containing 10 mM MgCl 2, 100 mM NaCl, and 20 M GTP. The membranes were incubated for 2 h on ice in wells precoated with specific antibodies to G i1␣ and G i2␣. The wells were washed with phosphate buffer containing 0.05% Tween 20, and the radioactivity from each well was counted by liquid scintillation.
Assay of adenylyl cyclase activity. Adenylyl cyclase activity was determined as described previously by measurement of [ 32 P]cAMP formation from [ 32 P]ATP in COS-1 cell membranes. Activity was measured in the presence of 1 mM ATP, 2 mM cAMP, 0.1 mM GTP, 0.1 mM IBMX, 10 M forskolin, 5 mM MgCl 2, 100 mM NaCl, 5 mM creatine phosphate, 50 U/ml creatine phosphokinase, and [ 32 P]ATP (4 ϫ 10 6 cpm). Membranes were incubated with the reaction mixture at 37°C for 10 min, and the reaction was terminated by the addition of 100 l of 2% SDS, 45 mM ATP, and 1.5 mM cAMP. [ 32 P]cAMP was purified by chromatography using Dowex/ alumina double column (9) (10) (11) domain of rat NPR-C was used as a guide in the construction of the NPR-C mutants. The mutations consisted of substitutions of leucine for single or adjacent basic amino acid residues at the NH 2 -terminal and COOH-terminal motif of this sequence (Fig. 1) . In seven mutants (mutant 3 to mutant 9), single or adjacent basic amino acid residues at the NH 2 Fig. 2Aa for leucine-substituted mutants 3 to 9 (see Fig. 1 ) and in Fig. 2Ab (Fig. 3) . Deletion of 11 COOH-terminal amino acid residues (E 486 to A
496
, mutant 1) did not affect G␣ i1 activity but significantly increased G␣ i2 activity (Fig. 3) . However, deletion of the 17-amino acid sequence in the middle region (R 469 to A
, mutant 2) corresponding to the active synthetic peptide completely inhibited G␣ i1 and G␣ i2 activities.
Substitution of single NH 2 -terminal arginine residues of this sequence (R469L or R470L, mutants 3 and 4) slightly reduced G␣ i1 and G␣ i2 activities (11 Ϯ 3 to 22 Ϯ 5%), whereas substitution of both residues (R469L and R470L, mutant 5) abolished G␣ i1 and G␣ i2 activities (Fig. 3) . Substitution of H 481 (H481L, mutant 6) or R 482 (R482L, mutant 7) in the COOH-terminal motif decreased G␣ i1 and G␣ i2 activities by 35 Ϯ 4 to 54 Ϯ 6%, respectively, whereas substitution of both of these residues (mutant 8) abolished G protein activity (Fig. 3) . Substitution of the ultimate arginine residue (R485L) in the COOH-terminal motif (mutant 9) also abolished G protein activity.
Activation of PLC-␤ by wild-type and mutant NPR-C.
Activation of PLC-␤ by wild-type and mutant NPR-C closely paralleled activation of G i1 and G i2 . cANP4-23 stimulated PLC-␤ activity in a concentration-dependent fashion (Fig. 4) . PLC-␤ activity was previously shown to reflect activation of the PLC-␤3 isoform by the ␤␥-subunits of G i1 and G i2 (6) (7) (8) 11) . Deletion of 11 COOH-terminal amino acid residues (E 486 to A 496 , mutant 1) augmented PLC-␤ activity, shifting the concentration-response curve to the left (Fig. 4) . However, deletion of 28 COOH-terminal amino acid residues, including the 17-amino acid sequence in the middle region (R 469 to A 496 , mutant 2), completely inhibited cANP4-23-stimulated PLC-␤ activity (Fig. 4) .
Substitution of single NH 2 -terminal arginine residues (R469L or R470L, mutants 3 and 4) had no effect on cANP4-23-stimulated PLC-␤ activity (Fig. 5) , whereas substitution of both arginine residues (R469L and R470L, mutant 5) abolished PLC-␤ activity (Fig.  5) . Substitution of H 481 (H481L, mutant 6) in the COOH-terminal motif caused a slight decrease in PLC-␤ activity, whereas substitution of the adjacent arginine residue (R482L, mutant 7) abolished PLC-␤ activity at lower concentrations of cANP4-23 and inhibited activity at the highest concentration (1 M) by 51 Ϯ 3% (Fig. 5) . Substitution of adjacent basic residues in the motif (H481L and R482L, mutant 8) abolished PLC-␤ activity (Fig. 5) . Substitution of the ultimate arginine residue (R485L) in the motif (mutant 9) abolished PLC-␤ activity at all but the highest concentration of cANP4-23 (Fig. 5B) .
Inhibition of adenylyl cyclase by wild-type and mutant NPR-C. As shown previously, inhibition of adenylyl cyclase activity by cANP4-23 was mediated by the ␣-subunits of G i1 and G i2 (2, 9, 10, 11, 13) . Inhibition of forskolin-stimulated adenylyl cyclase activity via wild-type and mutant NPR-C was examined at the highest concentration of cANP4-23 (1 M). At this concentration, cANP4-23 inhibited forskolin-stimulated adenylyl cyclase activity by 69 Ϯ 2% in COS-1 cells expressing wild-type NPR-C (Fig. 6) . Deletion of 11 COOH-terminal amino acid residues (E 486 to A 496 , mutant 1) caused significantly greater inhibition of adenylyl cyclase activity (91 Ϯ 3 vs. 69 Ϯ 2% for wild-type NPR-C; P Ͻ 0.01) (Fig. 6) . In contrast, deletion of 28 COOH-terminal amino acid residues, including the 17-amino acid sequence in the middle region (R 469 to A
496
, mutant 2), abolished inhibition of adenylyl cyclase by cANP4-23 (Fig. 6) .
Substitution of single NH 2 -terminal arginine residues (R469L or R470L, mutants 3 and 4) significantly decreased the inhibition of adenylyl cyclase (39 Ϯ 4 and 41 Ϯ 4% vs. 69 Ϯ 2% for wild-type NPR-C; P Ͻ 0.01) (Fig. 6 ), whereas substitution of both arginine residues (R469L and R470L, mutant 5) abolished inhibition of adenylyl cyclase (Fig. 6) . Substitution of H 481 (H481L, mutant 6) or R 482 (R482L, mutant 7) in the COOHterminal motif decreased the inhibition of adenylyl cyclase (35 Ϯ 5 and 59 Ϯ 4%, respectively, vs. 69 Ϯ 2% for wild-type NPR-C), whereas substitution of both residues (H481L and R482L, mutant 8) abolished inhibition of adenylyl cyclase (Fig. 6) . Substitution of the ultimate arginine residue (R485L) in the COOH-terminal motif (mutant 9) abolished inhibition of adenylyl cyclase (Fig. 6 ). 
DISCUSSION
Four peptides derived from various regions of the intracellular domain of rat NPR-C were recently shown to inhibit adenylyl cyclase activity in rat heart and vascular smooth muscle membranes (17 ), a 17-amino acid peptide derived from the middle region of the intracellular domain, was closely similar to the 17-amino acid peptide derived from the middle region of human NPR-C previously shown by us to activate selectively G i1 and G i2 , stimulate PLC-␤3 activity, and inhibit adenylyl cyclase activity (9) . We have now shown by deletion and site-directed mutagenesis of rat NPR-C expressed in COS-1 cells that only this 17- ) were essential to enable the receptor in situ to activate G protein and effector enzymes. Furthermore, deletion studies indicated that the 11-amino acid COOH-terminal sequence of rat NPR-C possessed G protein inhibitory activity. A similar conclusion was reached in our earlier study from the use of the corresponding synthetic peptide (9) . Deletion of the entire 28-amino acid COOH-terminal sequence, which included the active 17-amino acid sequence, abolished G protein or effector enzyme activities.
Substitution of either NH 2 -terminal arginine residue in the active 17-amino acid sequence had a minimal effect, whereas substitution of both arginine residues (R 469 R
470
) virtually abolished agonist-stimulated G i1/2 and PLC-␤ activities or the inhibition of adenylyl cyclase activity. This implied that no sequence COOHterminal to these two arginine residues is capable by itself of sustaining receptor activity in situ, including sequence H 481 -H 492 , which was capable of inhibiting adenylyl cyclase activity when used as a synthetic peptide (17) .
Substitution of single amino acid residues in the COOH-terminal motif (H 481 RELR 485 or BBXXB) greatly decreased agonist-stimulated G i1/2 and PLC-␤ activities or inhibition of adenylyl cyclase activity. These single substitutions were more effective than the corresponding substitutions at the NH 2 -terminus of the active sequence. In effect, substitution of the ultimate arginine or adjacent basic residues of the COOHterminal motif abolished G protein and PLC-␤ activities and inhibition of adenylyl cyclase activity. This implied that no sequence NH 2 -terminal to this motif is capable of sustaining receptor activity in situ, including sequences K 461 -H 472 and R 469 -K 480 , which were capable of inhibiting adenylyl cyclase activity when used as synthetic peptides (17) .
Deletion studies suggested that the 11 COOH-terminal amino acid sequence (E 486 to A 496 ) adjacent to the BBXXB motif harbored inhibitory activity, reflected in greater activation of G i2 and PLC-␤ and greater inhibition of adenylyl cyclase upon deletion. Our previous studies showed that a synthetic peptide corresponding to this sequence decreased the ability of cANP4-23 or the active 17-amino acid peptide to activate G proteins (particularly G i2 ) and PLC-␤ or inhibit adenylyl cyclase (9) . It is possible that the BXB motif (R 490 S 491 H 492 ) within this sequence enables it to bind but not activate G proteins and thus function as a competitive inhibitor.
Although the nine NH 2 -terminal amino acid residues flanking the G protein-activating sequence were devoid of activity, they contain the only threonine residue in the intracellular domain. In preliminary studies, we have shown this residue to be critical to desensitization and internalization of NPR-C. Selective phosphorylation of this residue by cGMP-dependent protein kinase (PKG) induced translocation of NPR-C from the plasma membrane to the cytoplasm and inhibited cANP4-23-mediated stimulation of PLC-␤ activity (27) . NPR-C is abundantly expressed in various cells and is often coexpressed with the receptor guanylyl cyclases, NPR-B and/or NPR-A, which exhibit relatively high affinity for ANP and can generate cGMP (3, 5, 21) . Generation of cGMP would lead to PKG-dependent phosphorylation of NPR-C and internalization of both receptor and ligand, thereby reducing the availability of ANP. In gastrointestinal smooth muscle cells that express NOS-III, interaction of ANP with NPR-C induces G i1/2 -dependent activation of NOS and stimulation of cGMP that could lead to similar feedback phosphorylation and internalization of NPR-C (10, 24) .
In summary, the truncated intracellular domain of NPR-C contains several short cationic peptide sequences flanked by basic residues or motifs. Synthetic peptides derived from these sequences are capable of activating G i . Mutational and deletion studies of the intracellular domain of the receptor in situ, however, indicate that only one of these, the 17-amino acid sequence in the middle region of the intracellular domain consisting of two NH 2 -terminal arginine residues and the COOH-terminal motif, HRELR, is capable of selectively activating G i1 and G i2 . The study emphasizes that mutational and deletion studies on the receptor in situ are essential to define the functional significance of putative active sequences.
